OCR · GCSE · Biology

    Course version: J247 · Version from Sept 2018

    Describe the processes of discovery and development of potential new…

    Full specification wording

    Monitoring and maintaining health: describe the processes of discovery and development of potential new medicines (to include: preclinical and clinical testing)

    Drug development proceeds through structured preclinical and clinical phases to establish safety, efficacy, and dosage.

    • Point 22 of 29
    • 4 key terms

    Study notes

    From the teaching notes for this specification point.

    The idea

    Drug development proceeds through structured preclinical and clinical phases to establish safety, efficacy, and dosage. Preclinical testing takes place in laboratory settings, assessing the chemical on isolated human cells, cultured tissues, and live animals to determine basic efficacy, toxicity, and safe dosage ranges. If cleared, clinical trials commence on humans: Phase 1 administers very low doses to healthy volunteers to check safety and side effects; Phase 2 tests the drug on volunteer patients to evaluate clinical efficacy and refine dosage; Phase 3 conducts large-scale, double-blind trials comparing the drug against a placebo, where neither patients nor doctors know who receives the active drug, eliminating psychological and observer bias.

    What earns the marks

    • Describe preclinical testing in laboratories using cultured human cells, tissues, and live animals to evaluate toxicity, efficacy, and dosage.
    • Describe clinical trials Phase 1 on healthy human volunteers at very low doses to test safety and side effects.
    • Describe clinical trials Phase 2 and 3 on patients suffering from the target disease to test efficacy, determine optimum dosage, and monitor rare side effects.
    • Explain double-blind placebo-controlled trials, where neither patients nor doctors know who receives the real drug, eliminating bias.

    Common mistakes and how to put them right

    • Thinking Phase 1 clinical trials test whether the drug cures the illness, rather than checking safety on healthy volunteers.

    • Believing a placebo is a poison, rather than an inert substance (such as a sugar pill) containing no active medicine.

    Exam tips

    • Clearly distinguish between toxicity (is it harmful?), efficacy (does it work?), and dosage (how much is needed?).
    • Explain that double-blind trials eliminate psychological bias from patients (placebo effect) and subjective bias from doctors analysing results.

    Try the lesson

    The start of the Monitoring and maintaining health: describe the processes of discovery and development of potential new medicines (to include: preclinical and clinical testing) lesson, made from teaching notes for this specification point.

    Have a go first

    In the development of a potential new medicine, what is tested during the preclinical stage?

    Listen

    Drug development proceeds through structured preclinical and clinical phases to establish safety, efficacy, and dosage. Preclinical testing takes place in laboratory settings, assessing the chemical on isolated human cells, cultured tissues, and live animals to determine basic efficacy, toxicity, and safe dosage ranges. If cleared, clinical trials commence on humans: Phase 1 administers very low doses to healthy volunteers to check safety and side effects; Phase 2 tests the drug on volunteer patients to evaluate clinical efficacy and refine dosage; Phase 3 conducts large-scale, double-blind trials comparing the drug against a placebo, where neither patients nor doctors know who receives the active drug, eliminating psychological and observer bias. A strong answer earns marks for these points. Describe preclinical testing in laboratories using cultured human cells, tissues, and live animals to evaluate toxicity, efficacy, and dosage. Describe clinical trials Phase 1 on healthy human volunteers at very low doses to test safety and side effects. Describe clinical trials Phase 2 and 3 on patients suffering from the target disease to test efficacy, determine optimum dosage, and monitor rare side effects. Explain double-blind placebo-controlled trials, where neither patients nor doctors know who receives the real drug, eliminating bias. Exam tip: Clearly distinguish between toxicity (is it harmful?), efficacy (does it work?), and dosage (how much is needed?

    See it

    A top-to-bottom flowchart. The first box is preclinical testing in laboratories, which leads to testing on isolated human cells, cultured tissues and live animals, then to assessing toxicity, efficacy and dosage. From there the flow moves to Phase 1, giving very low doses to healthy volunteers, then to checking safety and side effects. Next is Phase 2 on volunteer patients, leading to evaluating clinical efficacy and refining dosage. This leads to Phase 3, large-scale double-blind trials, then to comparing the drug against a placebo, and finally to the point that neither patients nor doctors know who receives the active drug.
    The sequence of preclinical testing followed by clinical trial Phases 1, 2 and 3, including the double-blind placebo comparison.

    Key words

    Say what each word means before you turn the card.

    preclinical testing

    Try answering aloud or in your head before turning the card.

    clinical human trials

    Try answering aloud or in your head before turning the card.

    double-blind placebo trials

    Try answering aloud or in your head before turning the card.

    placebo

    Try answering aloud or in your head before turning the card.

    See every definition
    preclinical testing
    Takes place in laboratory settings, assessing the chemical on isolated human cells, cultured tissues, and live animals to determine basic efficacy, toxicity, and safe dosage ranges.
    clinical human trials
    Commence on humans if cleared, with Phase 1 administering very low doses to healthy volunteers to check safety and side effects.
    double-blind placebo trials
    Large-scale trials comparing the drug against a placebo, where neither patients nor doctors know who receives the active drug, eliminating psychological and observer bias.
    placebo
    An inert substance containing no active medicine, used in double-blind trials for comparison against the drug.

    Label the diagram

    Some boxes have lost their names. Pick the right name for each number.

    The diagram again, with 3 boxes numbered instead of named. A top-to-bottom flowchart. The first box is preclinical testing in laboratories, which leads to testing on isolated human cells, cultured tissues and live animals, then to assessing toxicity, efficacy and dosage. From there the flow moves to Phase 1, giving very low doses to healthy volunteers, then to checking safety and side effects. Next is Phase 2 on volunteer patients, leading to evaluating clinical efficacy and refining dosage. This leads to Phase 3, large-scale double-blind trials, then to comparing the drug against a placebo, and finally to the point that neither patients nor doctors know who receives the active drug.
    • 1Box 1

    • 2Box 2

    • 3Box 3

    0 of 3 labelled

    There is more to this lesson

    The full lesson goes on to check your understanding and help you earn the marks. Create a free account to carry on, with your progress saved.

    Carry on with the full lesson

    A week of Premium from your first lesson · Then the free plan continues · No card, no charge

    Test your understanding of Monitoring and maintaining health: describe the processes of discovery and development of potential new medicines (to include: preclinical and clinical testing)

    Active recall beats re-reading. Take an instant quiz now to test what you’ve learned and lock it into long-term memory.

    Take topic quiz

    A week of Premium from your first lesson · Then the free plan continues · No card, no charge